TTP stands for thrombotic thrombocytopenic purpura, a rare and life-threatening blood disorder in which tiny clots form throughout the body’s small blood vessels. Without treatment, only about 1 in 10 people survive an acute episode. With prompt treatment, that number flips: 8 or 9 out of 10 people survive.
TTP belongs to a family of conditions called thrombotic microangiopathies, where damage to small blood vessels triggers abnormal clotting. What makes TTP distinct is its cause: the body loses the ability to process a sticky clotting protein, and the consequences cascade quickly.
What Happens in the Body
The core problem in TTP is a severe shortage of an enzyme called ADAMTS13. This enzyme has one job: breaking down a large, sticky clotting protein (von Willebrand factor) into smaller, less dangerous pieces. When cells lining blood vessels are stimulated, they release an ultra-large form of this protein that is extremely prone to grabbing platelets and triggering clots. Normally, ADAMTS13 chops these oversized molecules down almost immediately.
In TTP, ADAMTS13 activity drops below 10% of normal, and often below 5%. Without enough enzyme, those ultra-large sticky proteins accumulate in the bloodstream. Platelets latch onto them and form microscopic clots in small blood vessels throughout the body, particularly in the brain, kidneys, and heart. This uses up platelets rapidly (causing dangerously low platelet counts) and shreds red blood cells as they squeeze past the clots (causing a type of anemia called microangiopathic hemolytic anemia).
Most cases are immune-mediated, meaning the body’s own immune system produces antibodies that attack and disable ADAMTS13. This form is called immune TTP, or iTTP. A much rarer form, congenital TTP, results from inherited genetic mutations that prevent the body from making functional ADAMTS13 in the first place.
How TTP Differs From Similar Conditions
TTP is sometimes confused with hemolytic uremic syndrome (HUS), since both involve tiny blood clots, low platelets, and destroyed red blood cells. The distinction comes down to what’s driving the process. TTP results from severe ADAMTS13 deficiency. Typical HUS is triggered by toxins from certain E. coli bacteria. A third condition, atypical HUS, stems from problems with the complement system, a different branch of immune defense entirely.
Clinically, TTP tends to cause more severe neurological symptoms and deeper drops in platelet counts, while HUS more commonly causes acute kidney injury. In practice, though, the overlap can make it difficult to tell them apart based on symptoms alone, which is why lab testing for ADAMTS13 activity is so important.
Symptoms and the Classic Pentad
Textbooks describe a classic “pentad” of five TTP features: hemolytic anemia with fragmented red blood cells, low platelet count, neurological problems, fever, and kidney dysfunction. In reality, only about 7% of patients show up with all five at once. Most people present with just the first two, often alongside neurological symptoms that range from headaches and confusion to seizures or stroke-like episodes.
Other common signs include purpura (small purple or red spots on the skin from bleeding under the surface), fatigue, and shortness of breath from anemia. Symptoms can develop suddenly and worsen rapidly, which is why TTP is treated as a medical emergency.
How TTP Is Diagnosed
Diagnosis starts with blood work showing two hallmarks: a very low platelet count with no other obvious explanation, and evidence that red blood cells are being physically torn apart. A blood smear examined under a microscope reveals schistocytes, which are fragments of shattered red blood cells. In confirmed TTP cases, schistocytes typically make up about 6% of red blood cells on a smear, compared to less than 1% in other conditions that cause low platelets.
The definitive test is measuring ADAMTS13 activity. An activity level below 10% is almost exclusively seen in TTP and is currently the only lab test that can confirm or rule out the diagnosis. At a cutoff below 5%, diagnostic accuracy improves even further. Because these results can take days to come back, doctors use scoring tools to estimate the likelihood of TTP and decide whether to start treatment immediately.
The most widely used is the PLASMIC score, which assigns one point each for seven criteria: platelet count below 30,000, signs of red blood cell destruction, no active cancer in the past year, no organ or stem cell transplant history, a specific red blood cell size measurement, normal clotting time, and kidney function that isn’t severely impaired. A score of 6 or 7 indicates high risk for severe ADAMTS13 deficiency, while 0 to 4 suggests low risk.
Treatment for Acute Episodes
The cornerstone of TTP treatment is therapeutic plasma exchange, sometimes called plasmapheresis. This procedure removes the patient’s plasma (which contains the antibodies attacking ADAMTS13 and the dangerous ultra-large clotting proteins) and replaces it with donor plasma that contains functional ADAMTS13. Treatment typically involves daily sessions, each processing 1 to 1.5 times the patient’s total plasma volume, and continues until platelet counts stabilize.
Steroids are added as standard practice to suppress the immune attack on ADAMTS13. For immune TTP specifically, guidelines from the International Society on Thrombosis and Haemostasis also support adding two additional therapies. The first is rituximab, a medication that targets the immune cells responsible for producing the harmful antibodies. The second is caplacizumab, an FDA-approved drug that blocks the ultra-large clotting protein from binding to platelets, essentially preventing the tiny clots from forming in the first place.
In clinical trials, caplacizumab led to faster platelet recovery, zero TTP-related deaths compared to three in the placebo group, and significantly fewer recurrences during treatment (about 4% versus 38%). Patients receive it as an injection before and after plasma exchange, then daily for 30 days after their last exchange session.
Relapse and Long-Term Outlook
TTP can relapse, sometimes months or years after the initial episode. Relapse happens when ADAMTS13 activity drops again, usually because the immune system resumes its attack on the enzyme. People who have recovered from TTP typically have their ADAMTS13 levels monitored over time. If levels fall without symptoms, this is called asymptomatic ADAMTS13 deficiency, and preemptive treatment with rituximab may be recommended to prevent a full relapse.
Before plasma exchange became available, TTP was nearly always fatal. Modern treatment has transformed it into a survivable condition with a mortality rate around 10%. The key factor in outcomes is speed. Because organ damage accumulates as long as the tiny clots keep forming, treatment typically begins as soon as TTP is suspected, often before ADAMTS13 results are available. People who survive an acute episode generally recover fully, though they need ongoing monitoring given the risk of relapse.